North Chicago- June 27, 2024- AbbVie announced the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius’ lead investigational asset is CEL383, a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1(TREM1) antibody that has completed a Phase 1 clinical study for the treatment of Inflammatory Bowel Disease (IBD).
However, Researchers identified TREM1 as a key disease driver gene in IBD, expressing it on inflammatory monocytes and neutrophils. In these and other cell types, TREM1 is upstream of multiple known inflammatory pathways and amplifies inflammation.
“Given the potential relevance of TREM1 as a key driver of inflammation and pathology in IBD and other conditions, we are eager to advance the development of CEL383 with a goal of helping more patients with IBD achieve remission,” said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie.
Also Read: AbbVie Launches Contest to Empower People Living with Migraine in their Careers
“AbbVie shares our excitement about the potential of TREM1 inhibition for patients with inflammatory disease,” said Tariq Kassum, M.D., chief executive officer, Celsius Therapeutics. “I’d like to thank the Celsius team for their relentless efforts in the discovery of CEL383. We look forward to the further development of this promising program, which we hope will offer a new approach to the treatment of IBD.”
